BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 19060535)

  • 1. Out with the old, in with the new: immunosuppression minimization in children.
    Sarwal MM
    Curr Opin Organ Transplant; 2008 Oct; 13(5):513-21. PubMed ID: 19060535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term maintenance therapy with calcineurin inhibitors: an update.
    Campistol JM
    Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for immunosuppression in lung transplantation.
    Hopkins PM; McNeil K
    Curr Opin Organ Transplant; 2008 Oct; 13(5):477-83. PubMed ID: 19060529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can the early elimination of calcineurin inhibitors result in clinical benefits?
    Weir MR
    Transplant Proc; 2010 Nov; 42(9 Suppl):S16-20. PubMed ID: 21095444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study of everolimus with calcineurin inhibitor-free immunosuppression in maintenance heart transplant patients: results at 2 years.
    Engelen MA; Amler S; Welp H; Vahlhaus C; Gunia S; Sindermann JR; Rothenburger M; Stypmann J
    Transplantation; 2011 May; 91(10):1159-65. PubMed ID: 21478817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus and minimization of cyclosporine in renal transplantation: 24-month follow-up of the EVEREST study.
    Ponticelli C; Salvadori M; Scolari MP; Citterio F; Rigotti P; Veneziano A; Bartezaghi M;
    Transplantation; 2011 May; 91(10):e72-3. PubMed ID: 21540717
    [No Abstract]   [Full Text] [Related]  

  • 8. Steroid avoidance or withdrawal in kidney transplantation.
    Pascual J
    Curr Opin Organ Transplant; 2011 Dec; 16(6):600-5. PubMed ID: 21971514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
    Wali RK; Weir MR
    Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
    Hanto DW; Chudzinski R
    Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
    [No Abstract]   [Full Text] [Related]  

  • 12. Rationale and criteria of eligibility for calcineurin inhibitor interruption following kidney transplantation.
    Danger R; Giral M; Soulillou JP; Brouard S
    Curr Opin Organ Transplant; 2008 Dec; 13(6):609-13. PubMed ID: 19060551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in immunosuppression for pancreas transplantation.
    Singh RP; Stratta RJ
    Curr Opin Organ Transplant; 2008 Feb; 13(1):79-84. PubMed ID: 18660711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steroid-free maintenance immunosuppression and ABO-incompatible transplantation.
    Gloor J; Matas AJ
    Transplantation; 2010 Mar; 89(6):648-9. PubMed ID: 20010327
    [No Abstract]   [Full Text] [Related]  

  • 15. CNIs: immediate benefits but storing problems for the future?
    Kiuchi T
    Transplantation; 2008 Oct; 86(8):1026-7. PubMed ID: 18946338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance immunosuppression regimens: conversion, minimization, withdrawal, and avoidance.
    Yang H
    Am J Kidney Dis; 2006 Apr; 47(4 Suppl 2):S37-51. PubMed ID: 16567240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological risks of minimization strategies.
    Snanoudj R; Tinel C; Legendre C
    Transpl Int; 2015 Aug; 28(8):901-10. PubMed ID: 25809144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcineurin inhibitors in liver transplantation: to be or not to be.
    Castroagudín JF; Molina E; Varo E
    Transplant Proc; 2011; 43(6):2220-3. PubMed ID: 21839238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus-based, calcineurin-inhibitor sparing immunotherapy, long-term (6-year) results.
    Conti DJ; Petrov R; Elbalhoul O; Gallichio M
    Transpl Immunol; 2008 Nov; 20(1-2):12-3. PubMed ID: 18793727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there such a thing as protocol immunosuppression in liver transplantation?
    McCaughan GW; Sze KC; Strasser SI
    Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):1-4. PubMed ID: 25164689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.